New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
18:04 EDTRDUSRadius Health withdraws registration statement on form S-1
In a regulatory filing Radius said: Radius Healtth hereby applies for withdrawal of the company’s registration statement on Form S-1 filed with the Securities and Exchange Commission on February 6, 2012 and amended on September 28, October 19 and November 7. Pursuant to Rule 477 under the Securities Act of 1933, as amended the company is withdrawing the Registration Statement, which has not been declared effective, because the proposed public offering under the Registration Statement was abandoned due to general market conditions. Since the Registration Statement was not declared effective by the Commission, no shares of common stock as described in the Registration Statement were sold. In addition, the Company hereby applies for withdrawal of the Company’s Registration Statement on Form 8-A, filed with the Commission on November 5.
News For RDUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
09:42 EDTRDUSBarclays biotech analysts hold an analyst/industry conference call
Biotech Analyst Research Team, along with Dr. Felicia Cosman, an osteoporosis specialist and endocrinologist at the Helen Hayes Hospital in New York and Professor of Medicine at Columbia University College of Physicians and Surgeons, discuss Radius Health's Abaloparatide Phase 3 results and market opportunity on an Analyst/Industry conference call to be held on June 29 at 2:30 pm.
June 22, 2015
10:00 EDTRDUSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:26 EDTRDUSRadius Health downgraded to Hold from Buy at Maxim
Subscribe for More Information
June 18, 2015
16:24 EDTRDUSOn The Fly: Top stock stories for Thursday
Stocks began the session in positive territory, adding to the late day move yesterday that followed Fed comments about the central bank's plans to raise benchmark interest rates gradually. Today's rally was broad based, as all 10 S&P sectors were in positive ground and the Nasdaq closed at a new all-time high. There were the usual headlines concerning Greece, but for at least one day, the U.S. market was able to ignore the European noise. ECONOMIC EVENTS: In the U.S., the consumer prices index rose 0.4% in the month of May, versus expectations for a 0.5% increase. The core reading, which removes food and energy prices, rose 0.1%, versus the expected increase of 0.2%. Initial jobless claims dipped 12,000 to 267,000 in the week ended June 13, versus expectations for 277,000 first-time claims. The Philadelphia Fed manufacturing survey climbed 8.5 points to 15.2 in June, topping expectations for a reading of 8. The leading indicators rose 0.7% to 123.1 in May, topping expectations for a rise of 0.4%. In Europe, International Monetary Fund chief Christine Lagarde reportedly said Greece won’t be given a grace period if it fails to make its scheduled payment to the fund on June 30. Meanwhile, finance ministers of euro area member states met today, after which Agence France-Presse reported that the talks ended with no deal on Greece. Bloomberg subsequently said that euro leaders plan to hold a summit to discuss Greece this coming Monday. COMPANY NEWS: Shares of Oracle (ORCL) dropped $2.17, or 4.84%, to $42.74 after the enterprise software, hardware and IT services provider reported lower than expected fourth quarter earnings per share and gave a lower than expected forecast for profit in its new quarter... General Motors (GM) announced that Fitch has raised the credit ratings of both GM and GM Financial to investment grade, meaning the corporate credit ratings for GM are now investment grade with all major rating agencies. Meanwhile, Reuters reported, citing several sources familiar with the matter, that the automaker has hired Goldman Sachs (GS) and Morgan Stanley (MS) to advise it as Fiat Chrysler (FCAU) CEO Sergio Marchionne attempts to gain the support of GM investors with the goal of forcing merger discussions with GM's board... Fitness tracker maker Fitbit (FIT) surged 48.4% to close at $29.68 in its first day of public trading. The company priced its initial public offering at $20 per share, topping expectations, and its closing price gives it a market value near $6B. MAJOR MOVERS: Among the notable gainers was Martha Stewart Living Omnimedia (MSO), which rose $1.35, or 26.27%, to $6.44 after The Wall Street Journal reported the company was nearing a deal to be acquired by Sequential Brands (SQBG), though the Journal said it was unable to learn the terms of the potential deal being discussed. Sequential Brands (SQBG) shares added 12.4% to close at $16.04 following the report. Also higher was Radius Health (RDUS), which gained $7.81, or 15.1%, to $59.54 after the company announced results from the six-month extension study for abaloparatide, its experimental treatment for osteoporosis. Among the noteworthy losers was Bankrate (RATE), which fell $2.60, or 18.77%, to $11.25 and was downgraded to Neutral from Buy at SunTrust after the company's revenue outlook came in well below the consensus forecast. INDEXES: The Dow gained 180.10, or 1%, to 18,115.84, the Nasdaq rose 68.07, or 1.34%, to 5,132.95, and the S&P 500 added 20.80, or 0.99%, to 2,121.24.
09:04 EDTRDUSOn The Fly: Pre-market Movers
Subscribe for More Information
07:13 EDTRDUSRadius Health price target raised to $71 from $58 at Cantor
Cantor increased its price target on Radius after the company announced results from the abaloparatide six-month extension study that the firm views positively. Cantor expects the drug to be approved and predicts that it will reach the market sometime in late 2016. The firm thinks the company could sign a partnership deal, and it keeps a Buy rating on the shares.
06:46 EDTRDUSRadius Health to host conference call
Conference call to discuss positive top-line data from ACTIVExtend trial will be held on June 18 at 8:30 am. Webcast Link
June 17, 2015
20:05 EDTRDUSRadius Health announces positive top-line data from ACTIVExtend trial
Radius Health reports top line data from the first six months of ACTIVExtend and the 25 month combined data from ACTIVE and ACTIVExtend. Additionally, Radius is reporting new data from an exploratory analysis of major osteoporotic fractures in the ACTIVE trial. Radius previously reported positive results in December 2014 for the Phase 3 ACTIVE Trial – meeting the primary endpoint of new vertebral fracture reduction and secondary endpoints of non-vertebral fracture reduction and BMD increases at Spine, Femoral Neck and Total Hip. ACTIVExtend results show that the group previously treated with abaloparatide had no new vertebral fractures during the first six months on alendronate. From the start of the ACTIVE study, this group showed an 87% reduction in new vertebral fractures, 52% reduction in non-vertebral fractures, 48% reduction in clinical fractures, and a 58% reduction in major osteoporotic fractures over the 25-month period. A recent exploratory analysis of the ACTIVE trial showed that, for major osteoporotic fractures, there was a 67% reduction in major osteoporotic fractures for the abaloparatide treatment group versus placebo, and a 53% reduction in major osteoporotic fractures for the abaloparatide treatment group as compared to teriparatide. Over the 25-month period, patients in the abaloparatide-alendronate treatment group on average achieved a 12.8% increase in BMD at the lumbar spine, a 5.5% increase in BMD at total hip, and a 4.5% increase in BMD at the femoral neck. In this treatment group, 20.4% of patients achieved a 6% increase or greater in BMD at all three sites. The adverse events reported during the alendronate treatment period were consistent with previous clinical experience.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use